Last edition
News about "Alteogen "
Alteogen and Biogen Sign Deal for Hybrozyme-Based Subcutaneous Biologics
Alteogen signs a licensing deal with Biogen to develop and commercialise Hybrozyme-based subcutaneous biologics, granting rights for two products using the ALT-B4 platform.
Alteogen | 26/03/2026 | By News Bureau | 151
AstraZeneca Signs License Deal with Alteogen for ALT-B4
Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.
Alteogen | 18/03/2025 | By Aishwarya | 507
Alteogen Signs Exclusive License Deal with Daiichi Sankyo to Develop Subcutaneous ENHERTU
Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme Technology, to develop and commercialize a subcutaneous version of ENHERTU (fam-trastuzumab deruxtecan-nxki).
Alteogen | 11/11/2024 | By Aishwarya | 467
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy